Arteriocyte is now a part of Isto Biologics.

News + Views

Blog

ISTO Technologies to Present at OneMedPlace Emerging Company Finance Conference

Jan 1, 2009

St. Louis, MO (January 1, 2009) – ISTO Technologies, Inc announced today that it will participate in the 2nd Annual OneMedPlace Emerging Company Finance Conference in San Francisco, CA from January 13-14, 2009. Mitchell Seyedin, Ph. D., President and CEO of ISTO, will present on Tuesday, January 13th at 10:15 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell Street. The conference will bring together promising emerging healthcare and life science companies with strategic and venture investors focused on new technologies, emerging and micro cap public companies. Information about OneMedPlace and the conference may be found at www.onemedplace.com.

ISTO is a privately-held orthobiologics company based in St. Louis, MO. The Company’s discrete cell-based and biomaterial platforms encompass a number of technological breakthroughs that are poised to advance the practice of medicine by offering solutions for unmet and/or largely unsatisfied clinical needs in large orthopedic markets. ISTO’s mix of clinical stage, development stage and marketed products includes DeNovo® ET, engineered cartilage to repair and restore joint function in the knee, NuQu™, a cell-based injectable formulation of juvenile chondrocytes for nucleus regeneration of the spinal disc and InQu®, an osteobiologic bone graft Substitute and extender.

 

About ISTO
ISTO Technologies, Inc. is developing and marketing clinical solutions for sports medicine, spinal therapy, and trauma. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istobiologics.com or contact Scott Gill, Chief Financial Officer, at 314-995-6049.

To top